clinical trial · NCT05270460
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
GastroparesisPCS12852Placebo
brief summary
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic gastroparesis (DG) patients.
started
Mar 9, 2022
primary completion
Sep 29, 2022
completion
Oct 6, 2022
last updated
Jul 21, 2023
official title
A Phase 2A, Placebo-controlled, Randomized, Dose Response Study of the Safety, Pharmacokinetics and Efficacy of PCS12852 on Gastric Emptying Rate Assessed by 13C Spirulina GEBT in Patients With Moderate to Severe Gastroparesis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol